New Hope in Targeted Therapy for Histiocytosis

New Hope in Targeted Therapy for Histiocytosis

Oct 27, 2025

A new study from Memorial Sloan Kettering Cancer Center highlights the promise of ulixertinib, a targeted therapy drug that blocks ERK, for treating certain forms of histiocytosis, including Erdheim-Chester Disease (ECD). Led by Dr. Eli Diamond, a member of the ECDGA...